• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
LU Lu, GUO Qinglong, ZHAO Li. Advances of Src kinase family and paclitaxel resistance[J]. Journal of China Pharmaceutical University, 2017, 48(4): 377-383. DOI: 10.11665/j.issn.1000-5048.20170401
Citation: LU Lu, GUO Qinglong, ZHAO Li. Advances of Src kinase family and paclitaxel resistance[J]. Journal of China Pharmaceutical University, 2017, 48(4): 377-383. DOI: 10.11665/j.issn.1000-5048.20170401
shu

Advances of Src kinase family and paclitaxel resistance

More Information
    Graphical Abstract
    • Abstract
  • Src family kinase(SFK)highly expresses in many types of cancers, broadly adjusting their malignant behaviors. Paclitaxel is a widely used chemical agent. However, because of constant resistance, the effect of paclitaxel has been greatly attenuated. The present review summaries the recent research progress of the structure and adjustment of SFK and the molecular mechanism of paclitaxel resistance, as well as the regulation of SFK on paclitaxel resistance, in order to provide new references and evidences upon the paclitaxel-based tumor therapy.
    • FullText(HTML)
    • References (86)
  • [1]
    Kim L,Song L,Haura E.Src kinases as therapeutic targets for cancer[J].Nat Rev Clin Oncol,2009,6(10):587-595.
    [2]
    Thomas SM,Brugge JS.Cellular functions regulated by Src family kinases[J].Annu Rev Cell Dev Biol,1997,13:513-609.
    [3]
    Johnson FM,Gallick GE.SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy[J].Anticancer Agents Med Chem,2007,7(6):651-659.
    [4]
    Nicolaou KC,Rodney GK,Pierre P.Taxoids:new weapons against cancer[J].Sci Am,1996,274(6):94-98.
    [5]
    Cortes J,Baselga J.Targeting the microtubules in breast cancer beyond taxanes:the epothilones[J].Oncologist,2007,12(3):271-280.
    [6]
    Armstrong DK,Bundy B,Wenzel L,et al.Intraperitoneal cisplatin and paclitaxel in ovarian cancer[J].N Engl J Med,2006,354(1):34-43.
    [7]
    Misiukiewicz K,Gupta V,Bakst R,et al.Taxanes in cancer of the head and neck[J].Anticancer Drugs,2014,25(5):561-570.
    [8]
    Khongkow P,Gomes A,Gong C,et al.Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance[J].Oncogene,2016,35(8):990-1002.
    [9]
    Furness S,Glenny A,Worthington H,et al.Interventions for the treatment of oral cavity and oropharyngeal cancer:chemotherapy[J].Cochrane Database Syst Rev,2010,8(9):CD006386.
    [10]
    Hickey B,Francis D,Lehman M.Sequencing of chemotherapy and radiotherapy for early breast cancer[J].Cochrane Database Syst Rev,2013,30(4):CD005212.
    [11]
    Sato S,Itamochi H.Ovarian cancer and drug resistance[J].Curr Obstet Gynecol Rep,2015,4(1):18-25.
    [12]
    Sen B,Johnson FM.Regulation of Src family kinases in human cancers[J].J Signal Transduct,2011,2011:1-14.
    [13]
    Ocaña A,Borrego MR,Gil-Martín M,et al.A phase I-II trial of dasatinib in combination with trastuzumab(T)and paclitaxel in the first line treatment of HER2 positive metastatic breast cancer(MBC)patients:GEICAM/2010-04[J].Cancer Res,2016,76(4):OT3-01-02.
    [14]
    Koch C,Anderson D,Moran M,et al.SH2 and SH3 domains:elements that control interactions of cytoplasmic signaling proteins[J].Science,1991,252(5006):668-674.
    [15]
    Kefalas P,Brown T,Brickell P.Signalling by the p60c-Src family of protein-tyrosine kinases[J].Int J Biochem Cell Biol,1995,27(6):551-563.
    [16]
    Stover DR,Furet P,Lydon NB.Modulation of the SH2 binding specificity and kinase activity of Src by tyrosine phosphorylation within its SH2 domain[J].J Biol Chem,1996,271(21):12481-12487.
    [17]
    Roskoski RJ. Src kinase regulation by phosphorylation and dephosphorylation[J].Biochem Biophys Res Commun,2005,331(1):1-14.
    [18]
    Stover DR,Liebetanz J,Lydon NB.Cdc2-mediated modulation of pp60c-src activity[J].J Biol Chem,1994,269(43):26885-26889.
    [19]
    Giannoni E,Taddei M,Chiarugi P.Src redox regulation:again in the front line[J].Free Radic Biol Med,2010,49(4):516-527.
    [20]
    Luttrell L.Transmembrane signaling by G proteincoupled receptors[J].Methods Mol Biol,2006,332:3-49.
    [21]
    Oneyama C,Hikita T,Enya K,et al.The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src[J].Mol Cell,2008,30(4):426-436.
    [22]
    Ingley E.Src family kinases:regulation of their activities,levels and identification of new pathways[J].Biochim Biophys Acta,2008,1784(1):56-65.
    [23]
    Ershler MA,Samokhvalov IM,Belyavsky AV,et al.Genomic structure and alternative splicing of the murine bhk/ctk/ntk gene[J].FEBS Lett,1995,375(1/2):50-52.
    [24]
    Wheeler D,Iida M,Dunn E.The role of Src in solid tumors[J].Oncologist,2009,14(7):667-678.
    [25]
    Ahluwalia MS,Groot J,Liu WM,et al.Targeting SRC in glioblastoma tumors and brain metastases:rationale and preclinical studies[J].Cancer Lett,2010,298(2):139-149.
    [26]
    Morgan L,Nicholson RI,Hiscox S.Src as a therapeutic target in breast cancer[J].Endocr Metab Immune Disord Drug Targets,2008,8(4):273-278.
    [27]
    Aleshin A,Finn RS.SRC:a century of science brought to the clinic[J].Trends Microbiol,2010,12(8):599-607.
    [28]
    Ishizawar R,Parsons SJ.c-Src and cooperating partners in human cancer[J].Cancer Cell,2004,6(3):209-214.
    [29]
    Horwitz S.Taxol(paclitaxel):mechanisms of action[J].Ann Oncol,1994,5(6):S3-S6.
    [30]
    Orr GA,Verdier-Pinard P,Mcdaid H,et al.Mechanisms of taxol resistance related to microtubules[J].Oncogene,2003,22(47):7280-7295.
    [31]
    Orr GA,Verdier-Pinard P,Mcdaid H,et al.Mechanisms of taxol resistance related to microtubules[J].Oncogene,2003,22(47):7280-7295.
    [32]
    Ahmed AA, Mills AD, Ibrahim AEK, et al. The extracellular atrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel[J].Cancer Cell,2007,12(6):514-527.
    [33]
    Rouzier R,Rajan R,Wagner P,et al.Microtubule-associated protein tau:a marker of paclitaxel sensitivity in breast cancer[J].Proc Natl Acad Sci U S A,2005,102(23):8315-8320.
    [34]
    Xie S,Ogden A,Aneja R,et al.Microtubule-binding proteins as promising biomarkers of paclitaxel sensitivity in cancer chemotherapy[J].Med Res Rev,2016,36(2):300-312.
    [35]
    Komlodi-Pasztor E,Sackett D,Wilkerson J,et al.Mitosis is not a key target of microtubule agents in patient tumors[J].Nat Rev Clin Oncol,2011,8(4):244-250.
    [36]
    Charles D, Sikic BI. Mechanisms of action of and resistance to antitubulin agents:microtubule dynamics,drug transport,and cell death[J].J Clin Oncol,1999,17(3):1061-1070.
    [37]
    Debernardis D,Graniela E,Feudis PD,et al.p53 Status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel[J].Cancer Res,1997,57(5):870-874.
    [38]
    Tabuchi Y,Matsuoka J,Gunduz M,et al.Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer[J].Int J Oncol,2009,34(2):313-319.
    [39]
    Song Z,Yao X,Wu M.Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis[J].J Biol Chem,2003,23(25):23130-23140.
    [40]
    Lens SMA, Wolthuis RMF, Klompmaker R, et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension[J].EMBO J,2003,22(12):2934-2947.
    [41]
    Ling X, Bernacki R, Brattain M, et al. Induction of survivin expression by taxol(paclitaxel)is an early event,which is independent of taxol-mediated G(2)/M arrest[J].J Biol Chem,2004,279(15).
    [42]
    Zaffaroni N,Pennati M,Colella G,et al.Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer[J].Cell Mol Life Sci,2002,59(8):1406-1412.
    [43]
    Lu J,Tan M,Huang WC,et al.Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to taxol resistance[J].Clin Cancer Res,2009,15(4):1326-1334.
    [44]
    Hsieh HP,Coumar MS,Chang CY,et al.Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers[J].Mol Cancer,2009,8(1):43.
    [45]
    Gillet JP,Gottesman MM.Mechanisms of multidrug resistance in cancer[J].BC Coach′s Perspective,2010,596:47-76.
    [46]
    Penson RT, Oliva E, Skates SJ, et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients:a study in serial samples[J].Gynecol Oncol,2004,93(1):98.
    [47]
    Linn S,Giaccone G,Diest PV,et al.Prognostic relevance of P-glycoprotein expression in breast cancer[J].Ann Oncol,1995,6(7):679-685.
    [48]
    Oguri T,Ozasa H,Uemura T,et al.MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer[J].Mol Cancer Ther,2008,7(5):1150-1155.
    [49]
    Yin S,Zeng C,Hari M,et al.Random mutagenesis of β-tubulin defines a set of dispersed mutations that confer paclitaxel resistance[J].Pharm Res,2012,29(11):2994-3006.
    [50]
    Ale S,Sung R,Shen P,et al.Conservation of the class I β-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers[J].Mol Cancer Ther,2002,1(2):215-225.
    [51]
    Chen T,Pengetnze Y,Taylor C.Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3[J].Mol Cancer Ther,2005,4(2):217-224.
    [52]
    Salzano G,Navarro G,Trivedi MS,et al.Multifunctional polymeric micelles Co-loaded with anti-survivin siRNA and paclitaxel overcome drug resistance in an animal model of ovarian cancer[J].Mol Cancer Ther,2015,14(4):1075-1084.
    [53]
    Le X,Mao W,Lu Z,et al.Dasatinib induces autophagic cell death in human ovarian cancer[J].Cancer,2010,116(21):4980-4990.
    [54]
    Nam S,Williams A,Vultur A,et al.Dasatinib(BMS-354825)inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells[J].Mol Cancer Ther,2007,6(4):1400-1405.
    [55]
    Griffiths GJ,Koh MY,Brunton VG,et al.Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-x(L)and increases oxaliplatin- and Fas-induced apoptosis[J].J Biol Chem,2004,279(44):46113-46121.
    [56]
    Pengetnze Y,Steed M,Roby KF,et al.Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line[J].Biochem Biophys Res Commun,2003,309(2):377-383.
    [57]
    White E,Dipaola R.The double-edged sword of autophagy modulation in cancer[J].Clin Cancer Res,2009,15(17):5308-5316.
    [58]
    Levine B,Kroemer G.Autophagy in the pathogenesis of disease[J].Cell,2008,132(1):27-42.
    [59]
    Lu Z,Luo R,Lu Y,et al.The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells[J].J Clin Investig,2008,118(12):3917-3929.
    [60]
    Zou C, Jia L, Jin H, et al. Re-expression of ARHI(DIRAS3)induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel[J].BMC Cancer,2011,11(1):22-33.
    [61]
    Sun Y, Jin L, Liu J, et al. Effect of autophagy on paclitaxel-induced CaSki cell death[J].J CSU Med Sci,2010,35(6):557-565.
    [62]
    Zhang CC,Yang JM,White E,et al.The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells[J].Oncogene,1998,16(12):1617-1624.
    [63]
    Gruber D,Faire K,Bulinski C.Abundant expression of the microtubule-associated protein,ensconsin(E-MAP-115),alters the cellular response to Taxol[J].Cell Motility Cytoskeleton,2001,49(3):115-129.
    [64]
    Alli E,Bash BJ,Yang JM,et al.Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer[J].Cancer Res,2002,62(23):6864-6869.
    [65]
    Hage-Sleiman R,Herveau S,Matera EL,et al.Tubulin binding cofactor C(TBCC)suppresses tumor growth and enhances chemosensitivity in human breast cancer cells[J].BMC Cancer,2010,10:135-149.
    [66]
    Levi M, Maro B, Shalgi R. The involvement of Fyn kinase in resumption of the first meiotic division in mouse oocytes[J].Cell Cycle,2010,9(8):1577-1589.
    [67]
    Levi M,Shalgi R.The role of Fyn kinase in the release from metaphase in mammalian oocytes[J].Mol Cellular Endocr,2010,314(2):228-233.
    [68]
    George JA,Chen T,Taylor CC.Src tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells[J].Cancer Res,2005,65(22):10381-10388.
    [69]
    Zamora-Leon SP,Bresnick A,Backer JM,et al.Fyn phosphorylates human MAP-2c on tyrosine 67[J].J Biol Chem,2005,280(3):1962-1970.
    [70]
    Hanahan D,Weinberg RA.Hallmarks of cancer:the next generation[J].Cell,2011,144(5):646-674.
    [71]
    Le X,Mao W,Lu C,et al.Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2[J].Cell Cycle,2008,7(23):3747-3758.
    [72]
    Abramsson A,Lindblom P,Betsholtz C.Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors[J].J Clin Investig,2003,112(8):1142-1151.
    [73]
    Lu C,Shahzad MMK,Moreno-Smith M,et al.Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models[J].Cancer Biol Ther,2010,9(3):176-182.
    [74]
    Ai JH,Li Y,Huang JP,et al.MicroRNA-21 involves in VEGFR-1 activation induced epithelial-mesenchymal transition via Src in hepatocellular carcinoma[J].Int J Clin Exp Med,2016,9(2):1708-1715.
    [75]
    Singh JC,Jhaveri K,Esteva FJ.HER2-positive advanced breast cancer:optimizing patient outcomes and opportunities for drug development[J].Br J Cancer,2014,111(10):1888-1898.
    [76]
    Gordon EJ,Fukuhara D,Weström S,et al.The endothelial adaptor molecule TSAd is required for VEGF-induced angiogenic sprouting through junctional c-Src activation[J].Angiogenesis,2016,9(437):ra72.
    [77]
    Lin CC, Lee IT, Chi PL, et al. c-Src/Jak2/PDGFR/PKCδ-dependent MMP-9 induction is required for thrombin-stimulated rat brain astrocytes migration[J].Mol Neurobiol,2013,49(2):658-672.
    [78]
    Vispé S,Devries L,Créancier L,et al.Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA[J].Mol Cancer Ther,2009,8(10):2780-2790.
    [79]
    Belotti D,Vergani V,Drudis T,et al.The microtubule-affecting drug paclitaxel has antiangiogenic activity[J].Clin Cancer Res,1996,2(11):1843-1849.
    [80]
    Monache SD,Sanitàa P,Calgania A,et al.Src inhibition potentiates antitumoral effect of paclitaxel by blockingtumor-induced angiogenesis[J].Exp Cell Res,2014,328(1):20-31.
    [81]
    Lee F,Covello K,Castaneda S,et al.Synergistic antitumor activity of ixabepilone(BMS-247550)plus bevacizumab in multiple in vivo tumor models[J].Clin Cancer Res,2008,14(24):8123-8131.
    [82]
    Denisenkoa TV,Sorokinaa IV,Gogvadzea V,et al.Mitotic catastrophe and cancer drug resistance:a link that must to bebroken[J].Drug Resist Updat,2015,24:1-12.
    [83]
    Diao Y,Ma X,Min W,et al.Dasatinib promotes paclitaxel-induced necroptosis in lung adenocarcinoma with phosphorylated caspase-8 by c-Src[J].Cancer Lett,2016,379(1):12-23.
    [84]
    Xiao J,Xu M,Hou T,et al.Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling[J].Mol Med Rep,2015,12(3):3249-3256.
    [85]
    Fornier M,Morris P,Abbruzzi A,et al.A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer[J].Ann Oncol,2011,22(12):2575-2581.
    [86]
    Secord AA,Teoh DK,Barry WT,et al.A phase I trial of dasatinib,an Src-family kinase inhibitor,in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer[J].Clin Cancer Res,2012,18(19):5489-5498.
    • Related Articles

Catalog

    Get Citation
    PDF
    XML
    Article views (1146) PDF downloads (1993) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：290288

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return